Hypoxia Inducible Factors and Diabetes

Jenny E. Gunton

Affiliations

1 Centre for Diabetes, Obesity & Endocrinology, The Westmead Institute for Medical Research (WIMR), Westmead, Sydney, Australia
2 Westmead Hospital, Faculty of Medicine and Health, The University of Sydney, Australia
3 Garvan Institute of Medical Research, Darlinghurst, Sydney, Australia

Keywords

Diabetes, hypoxia inducible factor, beta-cell, insulin resistance, retinopathy, prolyl hydroxylase, von Hippel Lindau
Abstract

Hypoxia can be defined as a relative deficiency in the amount of oxygen reaching the tissues. Hypoxia inducible factors (HIFs) are critical regulators of the mammalian response to hypoxia. In normal circumstances, HIF-1α protein turnover is rapid, and hyperglycemia further destabilizes the protein. In addition to their role in diabetes pathogenesis, HIFs are implicated in development of the microvascular and macrovascular complications of diabetes. Improving glucose control in people with diabetes increases HIF-1α protein and has wide-ranging benefits, some of which are at least partially mediated by HIF-1α. Despite this, most strategies to improve diabetes or its complications via regulating HIF-1α have not proven currently clinically useful. The intersection of HIF biology with diabetes is a complex area in which many further questions remain, especially around the well-conducted and clearly-described discrepant effects of different methods of increasing HIF-1α, even within the same tissues. This review will present a brief overview of HIFs, discuss the range of evidence implicating HIFs in β-cell dysfunction, diabetes pathogenesis, and diabetes complications, and examine the differing outcomes of HIF-targeting approaches in these conditions.
INTRODUCTION
Diabetes prevalence is rising rapidly. In 2017 it was estimated that there were more than 450 million people with diabetes worldwide (1). Diabetes is the major cause of preventable blindness, end-stage renal failure, and preventable lower limb amputations (2). It is also associated with increased cardiovascular disease risk and decreased life expectancy (3).
Insulin is the major hormone produced from β-cells in the pancreatic islets of Langerhans. It lowers blood glucose by stimulating uptake into tissues including muscle and fat. Glucose transporter 4 (GLUT4) is responsible for most of this effect (4-6). In type 1 diabetes (T1D) and type 2 diabetes (T2D), there is not enough insulin to regulate blood glucose. In T1D, β-cells are lost due to autoimmune-mediated destruction (7, 8). In T2D, β-cells cannot release enough insulin to control glucose due to loss of cells, poor function, or both. Obesity increases risk for T1D (9) and T2D (10-12) in part by reducing insulin sensitivity; that is, insulin does not produce a normal decrement in blood glucose.

Hypoxia can be defined as deficiency in the amount of oxygen reaching target tissues. All mammals have processes to sense, respond to, and correct hypoxia. The most important component of this response is mediated by the hypoxia inducible factors (HIFs).

BASIC HELIX-LOOP-HELIX PER-ARNT-SIM (bHLH-PAS) TRANSCRIPTION FACTORS
HIFs are part of the bHLH-PAS family. These transcription factors function as obligate heterodimers with a class I plus a class II family member (13) (Figure 1A). Class I members include HIF-1α, Endothelial PAS domain protein 1 (EPAS1, also called HIF-2α and Member of PAS Superfamily 2 (MOP2)), Inhibitory PAS domain protein (IPAS, previously called HIF-3α), Aryl hydrocarbon Receptor (AhR), Single-Minded 1 (SIM1) and SIM2, Circadian Locomotor Output Cycles protein Kaput (CLOCK), and Neuronal PAS proteins 1-3 (NPAS). IPAS has inhibitory effects on HIF-1α, and HIF-2α and will not be discussed extensively in this review as it has no known role in diabetes. Class II members include Aryl hydrocarbon Receptor Nuclear
Translocator (ARNT, also called HIF-1β), ARNT2, and Bone Morphogenetic ARNT-Like 1 (BMAL1) and BMAL2.

HYPOXIA INDUCIBLE FACTOR 1α (HIF-1α)

The HIF1 transcription factor is formed by heterodimerisation of HIF-1α and HIF-1β (14, 15). The first papers to describe the role of HIF1 in hypoxic responses were the 1992 and 1993 seminal papers by Wang and Semenza (16, 17). In Hep3B cells, they described a nuclear factor with increased DNA-binding activity to the erythropoietin gene promoter after exposure to hypoxia.

Adequate oxygen is essential for numerous metabolic processes including mitochondrial generation of energy from glucose (stored as adenosine triphosphate (ATP)) (18). HIF-1α is essential for normal development; the whole-body knockout is embryonic lethal, with abnormal placental development and cardiac and vascular anomalies (19).

In the short term, humans respond to hypoxia by cells in the carotid body sensing lower oxygen and driving increased respiration. Carotid body function is reviewed in (20). The heterozygous HIF-1α-null mouse demonstrates that HIF1 has a critical role in carotid body development (21). HIFs are also the most important factors in mediating medium- to long-term responses to hypoxia.

With its critical role in oxygen sensing and hypoxia responses, it is not surprising that HIF-1α is regulated by many factors (22-29). In unstressed cells, HIF-1α is synthesised but the protein has a half-life of seconds to minutes (30). In the presence of oxygen, iron, and 2-oxo-glutarate (α-ketoglutarate), HIF-1α is hydroxylated on 2 proline residues (amino acids 402 and 564 of human HIF-1α) by prolyl hydroxylase domain (PHD) proteins, also called P4H proteins (31). These PHDs function as oxygen sensors to regulate HIF degradation (Figure 1B). Another layer of regulation is provided by enzymatic asparagine hydroxylation by a factor inhibiting HIF (FIH). Hydroxylated HIF-1α is bound by von Hippel Lindau (VHL) protein, leading to its ubiquitination and proteolysis (32). That interaction is inhibited by cobalt. Absence of sufficient
oxygen, iron, or 2-oxo-glutarate inhibits hydroxylation and thereby inhibits degradation. Similarly, lack of PHDs, FIH, or VHL impair HIF-1α degradation.

Un-proteolysed HIF-1α binds to HIF-1β (Figure 1B), which facilitates translocation to the nucleus, recruitment of transcriptional co-regulators, and regulation of gene expression.

**HIF-1α AND DIABETES**

Our work has found that *HIF-1B* mRNA is decreased in islets from people with T2D and is important for normal β-cell function (33, 34). That work showed that the bHLH-PAS family could regulate insulin secretion. With the heterodimeric composition of the active transcription factors, these findings led us to consider the partner or partners that are important for β-cell function. We discovered that deletion of HIF-1α in β-cells caused glucose intolerance in mice due to impaired glucose-stimulated insulin secretion (35). The role of HIF-1α in β-cell function and survival was also shown by observations of improved glucose tolerance in mice fed high-fat diet plus an iron chelator to increase HIF-1α protein stability (36). Improved glucose tolerance was due to better β-cell function. There was no benefit of iron chelation on β-cell function in mice with β-cell-specific deletion of HIF-1α.

Islets, and more particularly β-cells, ‘sense’ glucose by metabolising it to generate increased ATP. This sensing requires cellular glucose uptake followed by metabolism. Deletion of HIF-1α in β-cells decreased basal and glucose-stimulated ATP concentrations (35). Lower ATP generation, even when glucose is elevated, provides a mechanism for impaired glucose-stimulated insulin secretion with decreases in expression of the HIF-1 transcription factor. Higher intracellular ATP leads to closure of the inwardly rectifying potassium channel Kir6.2 and triggers the opening of voltage-dependent calcium channels in β-cells, especially L-type channels. The resulting calcium-influx stimulates insulin-vesicle fusion with the plasma membrane and insulin release.

First-phase insulin release is defined as insulin released within 10 minutes of a stimulus. Second phase is the insulin released after 10 minutes. First phase secretion is important for
maintenance of normal glucose tolerance. Loss of first phase release predicts future development of T1D and T2D (37-40). Mice lacking HIF-1α in β-cells have pronounced loss of first phase insulin release (35). Interestingly, loss of β-cell HIF-1α increases risk of T1D. NOD mice (a model of T1D) have low rates of diabetes development after exposure to the β-cell toxin streptozotocin or to viruses associated with human diabetes (41). In NOD mice, loss of HIF-1α in β-cells makes β-cells more susceptible to death, increasing their risk of spontaneous T1D, and risk of T1D after streptozotocin or coxsackievirus exposure (41).

Increasing HIF-1α has differing effects on glucose tolerance depending upon the method used, and these various outcomes will be discussed below.

**Glucose metabolism and HIF-1α**

Although prolyl-hydroxylases require 2-oxo-glutarate for activity, their regulation is more complex; other tricarboxylic acid intermediates (succinate and fumarate) compete with 2-oxo-glutarate for the binding pocket of PHDs and inhibit their function (42), permitting HIF-1α stability. Pyruvate also inhibits PHD-mediated hydroxylation of HIF-1α, thereby increasing protein availability (43).

Together, these effects might be predicted to increase HIF-1α availability with hyperglycemia. However, the opposite occurs. Once β-cell dysfunction is present, glucose rises, and HIF-1α protein is de-stabilised (44). Destabilisation of HIF-1α in diabetes is reviewed in detail in (45). Briefly, increases in 2-methylglyoxal that accompany hyperglycemia stimulate HIF-1α degradation and inhibits transcriptional activity. 2-methylglyoxal inhibits HIF-1α-HIF-1β dimer formation and recruitment of the p300/CBP regulatory complex (45). Thus, overall, hyperglycemia reduces HIF-1α activity.

Because lack of HIF-1α has been associated with decreased β-cell function and survival, glucose-induced inhibition of HIF-1α protein stability is also likely to hasten deterioration in β-cell function and speed progression to diabetes (Figure 2).

**Insulin signaling and HIF-1α**
In addition to the effects of glucose and its metabolites, insulin signaling upregulates HIF-1α via PI3K and MAPK phosphorylation pathways. Insulin resistance is present in ≥80% of people with T2D, and impaired insulin signaling would therefore contribute to the decreased HIF-1α seen in diabetes (35). Insulin deficiency associated with β-cell dysfunction or death would further decrease HIF-1α in the setting of diabetic hyperglycemia.

**Lipids and HIF-1α and β-cell function**

In addition to glucose effects on β-cell function (often called glucotoxicity) and HIF-1α protein stability, lipids affect both β-cell function (lipotoxicity) and HIF-1α (46). Metabolism of fatty acids, and particularly palmitate, cause decreased succinate. Succinate inhibits prolyl hydroxylation of HIF-1α, so decreased succinate permits increased HIF-1α proteolysis. This is also consistent with the hypothesis that gluco-lipo-toxicity accounts for the increased prevalence of diabetes seen in obesity.

**HIF-1α IN METABOLICALLY IMPORTANT TISSUES**

In addition to changes in β-cell function and gene expression seen with β-cell specific deletion of HIF-1α and with HIF-1α knockdown (35, 41), HIF-1α dysfunction is implicated in many of the metabolically important tissues and in many chronic complications of diabetes, discussed below.

**HIF-1α in muscle**

Muscle is the most important tissue in the body for insulin-stimulated glucose uptake, and therefore muscle plays an important role in developing insulin resistance (18, 47, 48). Insulin increases GLUT4 translocation to the myocyte cell membrane (5, 6). Muscle contraction during exercise increases oxygen utilization, leading to muscle hypoxia and HIF-1α protein induction (49, 50).

Exercise and/or hypoxia in muscle increases glycolysis, and chronic hypoxia can decrease mitochondrial content, with a larger proportion of energy supply presumed to derive from glycolysis (51). Together with muscle contraction, HIF-1α is important in maintenance of
muscle function and metabolism with hypoxia (49). However, HIF-1β is apparently dispensable for normal muscle fibre-type determination and insulin sensitivity, suggesting that an alternate HIF-1α partner is active in muscle (52).

Knockdown of HIF-1α in C2C12 cultured myocytes impairs GLUT4 translocation and glucose uptake (53). Mice with muscle-specific HIF-1α deletion have a shift from glycolysis with lactate export during exercise towards full oxidation of glucose, but at a long-term cost of extensive muscle damage (54). When young, they have improved exercise capacity, but this reverses as muscle damage sets in.

The MRL/Mpj strain of mice exhibit enhanced muscle function that is dependent upon HIF-1α (55). In mouse models, increasing HIFs by inhibiting PHDs improves the muscle response to exercise-induced injury (56) and to cryo-injury (57). In humans, the Pro582Ser polymorphism produces HIF-1α that is relatively degradation-resistant, increasing HIF-1α activity. This polymorphism is present at increased frequency in athletes, particularly elite endurance athletes (58).

Similar to observations in β-cells, increasing HIF-1α with hypoxia or VHL deletion has deleterious effects on muscle, but increasing HIF-1α with FIH or PHD deletion appears beneficial (59). Together, the data indicate that myocyte HIF-1α is necessary for normal muscle glucose uptake, insulin sensitivity, and prevention of muscle injury. With those features, it is surprising that there appears to be little published data describing HIF-1α levels in muscle in diabetes (Figure 3).

**HIF-1α and adipose tissue**

Effects in adipose tissue suggest that the relative hypoxia seen with obesity, which is associated with increased HIF-1α protein, leads to increased fibrosis in fat (60, 61). Similar increases in fibrosis are seen with overexpression of a constitutively active HIF-1α (62).

In one study, decreasing HIF-1α using a dominant-negative HIF-1α mutant improved obesity on high-fat diet (HFD) (63). That study reported that the HIF inhibitor PX-478 improved fat fibrosis and reduced HFD-induced weight gain. In contrast, another group found that
decreasing HIF-1α activity, also with a dominant-negative HIF-1α mutant, increased obesity with loss of normal brown-adipocyte phenotype in the interscapular brown fat pad (64). Both groups over-expressed HIF-1α with deletion of the DNA-binding domain including amino acids 30-389 and the reason for the different results remains unclear. Deletion of HIF-1α in adipocytes using the Cre-lox system with aP2-Cre causes mice to be resistant to weight gain, to have smaller fat pads, and to display better insulin sensitivity (65).

The metabolic effects of increasing HIF-1α in adipose tissue have also been examined (Figure 3). Mice with VHL deletion in adipocytes (mediated by aP2-Cre) are non-viable, dying between embryonic days 14.5 and 18.5 (66). Lethality is due to widespread haemorrhages, including in brain, liver, and skin. VHL-deficient embryos had increased expression of VEGF, which promotes blood vessel formation. Using a β-galactosidase reporter, the aP2-Cre driver has displayed strong embryonic expression in hindbrain and spine (66). This suggests that interpretation of aP2-Cre-driven mice and dominant-negative aP2-driven overexpression experiments could be complicated by its expression outside of adipose tissue.

**COMPLEX EFFECTS OF INCREASING HIF-1α**

Data regarding the effects of increasing HIF-1α is complex and will be discussed below. Some methods of increasing HIF-1α appear beneficial for β-cell function or metabolism, whereas others clearly are deleterious (67).

**Acute hypoxia**

Acute altitude exposure causes relative hypoxia, and acute hypoxia impairs glucose tolerance in most people. Oxygen is needed for glucose-metabolism in β-cells and therefore for glucose-sensing and insulin release. In people who usually reside at low altitude, spending time at high altitude, with its relative hypoxia, impairs glucose tolerance (68). Continuous glucose monitoring (CGM) assessed glucose in healthy people trekking upwards and found peak glucose levels after 6 days at 3600m altitude. After that, glucose homeostasis improved despite further increases in altitude (69). C-peptide, which is secreted in equi-molar amounts to insulin,
was reduced at 6 days, and then returned to levels similar to baseline. Glucose-stimulated insulin secretion was not measured.

The issue of β-cell function in hypoxic conditions is complex; people who normally live at high altitude have adaptations, and in some cases polymorphisms, and maintain normal glucose at altitude (68, 70, 71). Counter-intuitively, these people may show worse glucose tolerance at sea level. It is interesting to speculate that this might be because of de-stabilization of HIF-1α with greater oxygen availability.

In cultured β-cells and islets, severe hypoxia increases stabilisation of HIF-1α protein, but the response is insufficient to prevent apoptosis and cell death (72, 73). Hypoxia down-regulates the unfolded-protein response independently of HIF-1α and this may contribute to hypoxia-related β-cell death (74).

In contrast to very low oxygen tension (for example 1% or less), at 5% oxygen, HIF-1α improves β-cell gene expression and insulin release (35). In vivo, compensation by increased respiration rate and eventually increased red blood cell formation returns overall oxygen towards normal (75). The residual smaller degree of hypoxia would be more similar to the effects of milder degrees of hypoxia and could be followed by changes in gene expression which would promote glucose uptake and metabolism.

Separate from its effects on β-cell function, altitude exposure induces insulin resistance. Men living at sea-level exhibit increased insulin resistance after acute altitude increase. Insulin resistance was worst 2 days after altitude-exposure but had not returned to baseline after 7 days (70). Effects of altitude on insulin resistance appear to be longer-lasting than those on β-cell function. In the CGM study above, insulin resistance calculated by homeostasis model was worsened throughout the study despite glucose improving after 6 days (69). The reverse condition was tested by performing clamp studies on men with chronic airway disease and hypoxia before and after oxygen supplementation. Improving their oxygenation (i.e. decreasing hypoxia) improved their insulin sensitivity (76). Similar benefits are seen in people with obstructive sleep apnea who commence therapy.
**Heavy metals: cobalt and chromium**

Heavy metals such as cobalt and chromium also stabilise HIF-1α protein. At least a part of this mechanism is by interfering with the interaction between HIF-1α and VHL protein (32). In rats, cobalt causes deterioration in glucose tolerance, but at higher concentrations, glucose tolerance starts to improve, until toxicity is reached (77). Interestingly, chromium used to be a commonly sold nutritional supplement advertised for diabetes and lipids. However, serum chromium levels do not correlate with metabolic features in women with gestational diabetes (78), and randomised controlled trials of chromium supplementation in people with abnormal glucose tolerance show no beneficial effects on glucose homeostasis (79, 80), even with a documented rise in serum chromium (79). Both of these trials used chromium picolinate. A randomised controlled study of supplementation with brewer’s yeast (which contains high amounts of chromium) suggested beneficial effects (81), so the effects may depend on the method of administration.

**VHL protein**

In mice, deletion of VHL protein worsens β-cell function in studies using either RIP-Cre or PDX1-Cre to mediate β-cell-specific deletion (82-84). Effects range from severe β-cell dysfunction (82) to normal glucose tolerance until 6 months of age, and after that improved HbA1c and fasting glucose but worsened peak glucose (84). Effects of β-cell VHL deletion are ameliorated or abolished when β-cell HIF-1α is also deleted.

There is surprisingly little data about diabetes in people with VHL syndrome, a condition linked to tumor formation caused by mutations in the VHL gene. One paper examining pancreatic lesions reported that 2 of 17 patients with extensive pancreatic lesions had diabetes (85). A series of 158 patients reported 3 cases of diabetes, also occurring in conjunction with pancreatic lesions (86). Five of 175 patients (2.9%) is a low diabetes prevalence for average adult populations, but these patients were relatively young, so it remains possible that diabetes is more common with VHL syndrome than currently appreciated. A formal study testing glucose tolerance would be interesting.
An Arg200Trp mutation in VHL is responsible for some cases of Chuvash polycythaemia, an autosomal recessive condition with inappropriately high erythropoietin and red blood cell numbers (87). These people have increased GLUT1 expression, and improved glucose and HbA1c levels (88). Mice engineered with the same change have substantially improved glucose tolerance tests (88). This mutation demonstrates that absence (deletion) of VHL produces different effects than mutations impairing its action.

**Prolyl hydroxylase domain containing proteins (PHDs)**

As described above, PHDs function to hydroxylate HIF-1α on 2 important prolyl residues. PHD1, also known as Egl9 family hypoxia inducible factor 2 (EGLN2), has no identified human mutations. In mice, PHD1 deletion impairs normal oxidative muscle performance, but protects myofibers in the setting of otherwise lethal ischemia (89). On chow-diet, whole-body PHD1-null mice have decreased weight with worsened insulin sensitivity and glucose tolerance (90). These mice gain more weight when eating HFD, but after 11 weeks their glucose tolerance is significantly improved, accompanied by lower serum insulin (90).

PHD2, also known as EGLN1, hydroxylates proline residues in HIF-1α and HIF-2α. Mutations are responsible for some rare cases of familial erythrocytosis type 3 (91, 92). No cases of diabetes are reported in individuals with this disorder. PHD2 deletion in mice is embryonic lethal in mid-gestation. Heterozygous mice are healthy and have decreased tumour spread (93) and better protection from limb ischemia (94) than wild-type mice. Small-interfering RNA (siRNA)-mediated knockdown of PHD2 in 832/13 β-cells had no effect on glucose-stimulated insulin secretion (95). Overall, these results suggest no major role for PHD2 in glucose homeostasis.

There are no described human mutations in PHD3 (EGLN3), and its role in diabetes has not been extensively investigated. It suppresses insulin sensitivity in liver, and hepatic deletion enhanced HIF-2α stability, and thereby Irs2/Akt2 signalling (96). β-cell-specific effects of PHD3 have been reported in abstract form (97) and increased glycolysis and use of fatty acids for
energy were found. On normal diet, this had no deleterious effects, but with HFD, mice developed glucose intolerance.

**Asparagine hydroxylase**

FIH (also called HIF-1α inhibitor (HIF1AN)) hydroxylates asparagine residue 803 of HIF-1α (98). This inhibits HIF-1α transcriptional activity (99). FIH deletion in mice improves glucose tolerance, insulin sensitivity, and weight (59, 100). FIH can hydroxylate asparagine on other proteins, including members of the ankyrin family (101). It is therefore important to note that many effects of FIH deletion in murine embryonic fibroblasts are lost with co-deletion of HIF-1α (59).

**Iron chelation and dimethylxalylglycine (DMOG)**

PHDs and FIH require oxygen, iron, and 2-oxo-glutarate (α-ketoglutarate) to enzymatically hydroxylate HIF on proline and asparagine residues respectively. Decreasing iron availability increases HIF-1α protein, improving β-cell function in mice fed HFD and improving wound healing when topically applied in mice (35, 102, 103). Iron chelation also improved islet transplant outcomes by increasing HIF-1α (36).

The competitive PHD inhibitor DMOG improves wound healing on topical application (103), but it may impair functional β-cell differentiation (104). Islet transplantation has not been reported.

Overall, accumulation of hydroxylated HIF (as occurs with VHL deletion) is deleterious and accumulation of partially-hydroxylated HIF (as occurs with PHD or FIH deletion) appears beneficial.

**Overexpression of constitutively active HIF-1α**

Halberg et al. increased HIF-1α in adipose tissue by expressing HIF-1α without the oxygen degradation domain between amino acids 401 and 603 under control of the aP2 promoter (62). The effect was increased weight gain on chow and on HFD. HFD-fed mice had worsened glucose tolerance and increased liver lipid content. There was increased adipose tissue fibrosis and inflammation (62).
Conclusions about increasing HIF-1α

These different methods of increasing HIF-1α have widely varying outcomes, summarised in Figure 3. Briefly: hypoxia is deleterious due to insufficient oxygen. VHL deletion is also deleterious, suggesting that accumulation of hydroxylated HIF-1α causes metabolic deterioration. The Arg200Trp mutation in VHL, however, improves glucose tolerance.

Accumulation of HIF that occurs with impaired proline hydroxylation (as a result of deleting PHDs) is deleterious in PHD1-null mice, and an abstract reports PHD3 deletion is deleterious for β-cells. In contrast, inhibiting asparagine hydroxylation improves glucose tolerance, adiposity and muscle. Some PHD inhibitors also inhibit FIH, and these are largely beneficial.

HIF-2α

Unlike HIF-1α, HIF-2α expression is confined to vertebrates (105). The HIF2 transcription factor is composed of HIF-2α and HIF-1β. In mice, HIF-2α deletion is lethal due to impaired placental development and foetal anomalies (106). HIF-2α shares only 48% sequence homology with HIF-1α, but the DNA-binding sequences are more highly conserved (107). Gain of function mutations are associated with paraganglioma and phaeochromocytoma (108-110).

There are relatively few papers reporting a role of HIF-2α in diabetes. Gain-of-function changes in HIF-2α are associated with better metabolic adaptation to altitude in Tibetans (71). These variants promote glycolysis and are associated with increased serum lactate. Individuals with HIF-2α variants have a decreased diabetes risk at high altitude, with a seemingly paradoxical increased risk of diabetes at sea-level.

Brunt et al. overexpressed HIF-2α in pancreatic β-cells (111) using a PDX-Cre driver and found no change glucose tolerance or insulin sensitivity, suggesting that HIF-2α does not play a major role in β-cell function.
HIF-2α does regulate hepatic insulin sensitivity (112). In liver, HIF-2α regulated insulin sensitivity via insulin receptor substrate 2 and suppressed gluconeogenesis. In partnership with this effect, HIF-2α also inhibits glucagon stimulation of gluconeogenesis after feeding (113). In contrast, HIF-1α regulated only hepatic glycolysis, similar to its effects in β-cells (112).

A recent paper reported an age-related decline in hypothalamic HIF-2α levels that was associated with worsened weight gain, adiposity, and insulin sensitivity in response to HFD (114). The same paper reported that POMC neuron-specific deletion of HIF-2α increased fat mass and age-related weight gain with mild impairment of glucose tolerance and increased insulin resistance.

HIFS AND MICROVASCULAR COMPLICATIONS OF DIABETES

In addition to roles in pathogenesis of β-cell dysfunction, insulin resistance, and obesity, HIFs play roles in the complications of diabetes. The microvascular complications of diabetes (retinopathy, nephropathy, and neuropathy) occur in tissues with constitutively-active glucose transporters that lack substantial insulin-mediated glucose uptake. Given the ability of hyperglycemia to down-regulate HIF protein, as discussed above, the role of HIF in these complications is of interest.

HIFs and retinopathy

The retina experiences relative hypoxia at high glucose levels due to glucose-induced destabilisation of HIF-1α. Intensive diabetes therapy and the consequent improvement in glucose levels increases HIF-1α, which in turn facilitates new blood vessel growth and short-term retinopathy progression in experimental models (115) and in humans (116). It is important to note that despite increased short-term disease progression, people with more intensive glucose control have better long-term eye outcomes.

Cross-sectional data suggest that glucose variability, which would be predicted to cause fluctuations in HIF-1α protein, is associated with increased retinopathy (117). Higher day-to-day variation in fasting glucose prospectively predicts risk of retinopathy (118, 119). However, not
all studies find significant associations (120). Perhaps because CGM is a relatively recently developed technology, prospective long-term data are not yet available. Overall, a role for HIF and glucose variability is plausible; experimental intermittent hypoxia causes more HIF-1α fluctuation than continuous hypoxia of the same severity (121). Clinically, obstructive sleep apnea causes intermittent hypoxia and is associated with increased retinopathy (122), and people with sleep apnea who use their therapeutic masks more often have decreased retinopathy (123). However, compliance with sleep apnea therapy may correspond with compliance with other therapies, so this does not demonstrate causality.

HIF-1α is involved in pathogenesis of retinopathy in the animal model of hyperoxia-normoxia in neonatal rodents (124). In humans, retinopathy occurs in premature newborns who are treated with high oxygen concentrations (retinopathy of prematurity).

Ocular HIF-1α protein and its transcriptional target VEGF are increased in diabetic retinopathy (125). Neutralising antibodies directed against VEGF have markedly improved outcomes for proliferative diabetic retinopathy and for ‘wet’ macular oedema (126, 127), showing that this pathway is clinically important in human retinopathy.

PHD inhibition decreases retinopathy in a rat model (128). Increasing HIF-1α in the eye by inhibiting PHDs with dimethyloxalylglycine prevents oxygen-induced retinopathy (129). The HIF-1α Pro582Ser polymorphism confers resistance to hyperglycemia-mediated decreases in HIF-1α protein. This polymorphism associates with decreased risk of retinopathy (130). Overall, some methods of increasing HIF-1α are beneficial for retinopathy progression, and this indicates an area with scope for further research, especially around conditions with relatively less vascular retinal disease e.g. “dry” macula edema, or already lasered retinas.

**Nephropathy, diabetes, and HIFs**

In many countries, diabetes is the commonest cause of end-stage renal failure. Renal tubular fibrosis is an important contributor. Relative intra-renal hypoxia is present (131, 132), and increased HIF-1α in kidneys associates with increased renal fibrosis (131, 133). The relationship between HIF and renal fibrosis is reviewed in (134). Cellular communication network factor 2
(CCN2, also called connective tissue growth factor, CTGF) is a pro-fibrogenic agent involved in nephropathy pathogenesis (135). In hypoxia, CCN2 expression is directly regulated by HIF-1α (136).

SGLT2 inhibitors are a relatively new class of diabetes drug which have major reno-protective effects in diabetes (137). Empagliflozin and dapagliflozin are both reno-protective in animal models, and both decrease renal HIF-1α (138, 139). Since inhibiting HIF-1α ablated the protection (139), it is possible that the HIF-1α decrease is indirect, via diminishing relative hypoxia.

Overexpression of HIF-1α by deletion of renal VHL causes adverse renal outcomes (140). However, increasing HIF-1α with cobalt chloride improves renal outcomes in diabetes models (141, 142). The Pro582Ser polymorphism in HIF-1α that is associated with decreased retinopathy (130) is also associated with decreased nephropathy in human diabetes (143). These results suggest that analogous to the situation in β-cells, the method of increasing HIF-1α controls renal outcomes. Heterozygous HIF-1α deletion exacerbates renal ischemia-reperfusion injury, and in wild-type mice stimulators of HIF stabilization improve outcomes (144).

**Neuropathy and HIFs**

Peripheral neuropathy in diabetes is associated with changes in the small blood vessels supplying nerves. Hyperglycemia increases energy availability, which may induce mitochondrial dysfunction and increase reactive oxygen species. While there is transient HIF-1α induction following experimental diabetes onset (145), mice with peripheral nerve-specific HIF-1α deletion develop more severe nerve damage (146), consistent with a protective role for HIF-1α.

Other than pain, the major consequence of peripheral neuropathy is risk of foot ulcers. Diabetes is the commonest cause of preventable non-traumatic lower-limb amputations, causing >100,000 amputations yearly in the USA (147). There are several studies linking HIF to poor wound healing in diabetes (102, 148, 149), and HIF-1α is decreased in chronic foot ulcers (150). In diabetes, hyperbaric oxygen (which increases oxygen availability) paradoxically increases HIF-1α protein (148) and improves healing. Increasing HIF-1α with topical iron chelators
stimulated experimental wound healing in mice. The benefit was lost with myeloid cell-specific HIF-1α deletion (102).

**Macrovascular complications of diabetes**

Cardiovascular diseases are commonest cause of death in people with diabetes (151-153). Increased atherosclerosis, hypertension, and dyslipidemia all play roles. People with diabetes have worse outcomes after cardiac events, with poorer collateral vessel development, larger infarcts, and increased risk of heart failure (154). A number of hypoglycemic agents may decrease cardiac risk in type 2 diabetes (155, 156). Each hypoglycemic agent decreases blood glucose, consistent with their original therapeutic intent, but the decrease in adverse cardiovascular events is not proportional to changes in HbA1c, indicating that non-glucose effects are important. For example, canagliflozin and empagliflozin decrease death by >30% within the study period but only decrease HbA1c by 0.5-0.9%. Other agents with larger effects on glucose such as semaglutide are also beneficial, but have similar or smaller magnitude of effect on cardiac outcomes despite HbA1c benefits of >1.5%. The effects of these agents on HIF-1α protein is not reported.

HIF is important for normal remodelling in the cardiovascular system, as reviewed in (157). Cardiac-specific HIF-1α deletion causes worsened cardiac function in non-diabetic animals (158). Cardiac-specific deletion of HIF-1β in non-diabetic mice leads to cardiomyopathy with impaired cardiac lipid metabolism (159). Heterozygous whole-body deletion of HIF-1α increases risk of impaired cardiac function after diabetes induction (160).

Cardiac overexpression of HIF-1α improves cardiac function and outcomes in a rodent diabetes model (161). Patients with VHL syndrome, who have increased HIF-1α, appear to have reduced cardiovascular death, although this may be confounded by an increase in premature death from cerebral hemangioblastomas and malignancies (162).

**SUMMARY AND CONCLUSIONS**
HIFs play a role in the pathogenesis of β-cell dysfunction and diabetes. Hyperglycemia destabilizes HIF-1α protein, causing impaired hypoxia responses. HIF-1α plays a role in obesity and the ability of adipose tissue to compensate for increased mass without excess fibrosis and inflammation.

The complications of diabetes involve dysregulation of HIF-1α, both for macrovascular and microvascular complications, with decreased HIF-1α activity associated with most complications. However, for proliferative retinopathy, inhibiting VEGF action is beneficial for vision outcomes by decreasing bleeding neo-vasculature and retinal detachment. Deletion of HIF-1α worsens most diabetes complications, as well as β-cell function itself.

Given the adverse effects of decreased HIF-1α, it seems logical to consider whether increasing it is beneficial. So it is noteworthy that increasing HIF-1α by decreasing VHL has adverse consequences in most tissues. In contrast, increasing HIF-1α by decreasing or deleting FIH or the prolyl hydroxylases may have beneficial effects.

Severe hypoxia is harmful and cannot be fully compensated for by HIFs and their downstream effects. Accumulation of fully hydroxylated HIF-1α, as seen with VHL deletion, is also harmful. In contrast, accumulation of partially hydroxylated or un-hydroxylated HIFs seen with modest hypoxia, PHD deletion, FIH deletion, or PHD/ FIH inhibition have some beneficial effects. Gene expression studies suggest that different effects are observed with VHL deficiency, indicating that fully hydroxylated HIFs have quite different actions. Possibly, understanding these effects may help with treating VHL syndrome.

There are still areas of HIF biology that are not yet described or complicated by studies with conflicting results (see Figure 3). Because of the complex regulation involved in HIF pathways and across various tissues, further research is needed to understand whether any strategies for increasing HIF-1α protein may be used to decrease diabetes development or reduce risk of diabetes complications.
REFERENCES


29. Yuan Y, Hilliard G, Ferguson T, and Millhorn DE. Cobalt inhibits the interaction between hypoxia-inducible factor alpha (HIFalpha) and von Hippel-Lindau protein by direct binding to hypoxia-inducible factor-alpha. 2003;278(18):15911-6.


25


Rojas DR, Tegeder I, Kuner R, and Agarwal N. Hypoxia-inducible factor 1alpha protects peripheral sensory neurons from diabetic peripheral neuropathy by suppressing accumulation of reactive oxygen species. *J Mol Med (Berl)*. 2018;96(12):1395-405.


Figure 1. Basic helix-loop-helix Per-Arnt-Sim (bHLH-PAS) family and HIF-1 protein. A) bHLH-PAS family proteins work as heterodimers with a class I and a class II member. B) HIF-1α protein is regulated by iron and oxygen availability. In the presence of adequate oxygen, iron, and 2-oxo-glutarate (normoxia, left), little HIF-1α escapes rapid hydroxylation (OH), ubiquitination (Ub) by von Hippel Lindau protein (VHL), and proteolysis. With deficiency of iron (middle) or oxygen (right), HIF-1α protein accumulates, binds to HIF-1β, and then the dimer binds to hypoxia response elements (HRE) to regulate gene expression.

HIF, hypoxia inducible factor; AhR, aryl hydrocarbon receptor; SIM, single minded; CLOCK, circadian locomotor output cycles protein kaput; NPAS, neuronal PAS protein; ARNT, aryl hydrocarbon receptor nuclear translocator; BMAL = bone morphogenetic ARNT-like.
Figure 2. Interactions between diabetes, obesity, and HIFs. Insulin resistance and deficiency in diabetes are associated with destabilization of HIF proteins. While obesity exacerbates insulin resistance, it also promotes tissue hypoxia as well intermittent hypoxia through its association with sleep apnea. These concurrent outcomes mediate complex effects on diabetes progression and complications.
Figure 3. HIF-1α and diabetes – effects and unknowns. Purple OH indicates hydroxylation of HIF-1α on proline residues, and blue OH indicates hydroxylation on asparagine residues. In the liver, HIF-2α primarily mediates some effects, and not HIF-1α, as indicated. Red arrows indicate primarily deleterious effects of either increasing or decreasing hypoxia, green indicates beneficial effects, and ~ indicates neutral effects. Question marks indicate unknowns and areas for potential future investigation. † indicates that whole body hypoxia is decreased on chow, but improved on high fat diet. * Note
that while hypoxia is clearly a feature of macrovascular disease, hypoxic pre-exposure before the event (i.e. stroke or myocardial infarct) improves outcomes. Overall, fully hydroxylated HIF and severe hypoxia are both deleterious.